ECSP19072294A - Composición farmacéutica que comprende selexipag - Google Patents
Composición farmacéutica que comprende selexipagInfo
- Publication number
- ECSP19072294A ECSP19072294A ECSENADI201972294A ECDI201972294A ECSP19072294A EC SP19072294 A ECSP19072294 A EC SP19072294A EC SENADI201972294 A ECSENADI201972294 A EC SENADI201972294A EC DI201972294 A ECDI201972294 A EC DI201972294A EC SP19072294 A ECSP19072294 A EC SP19072294A
- Authority
- EC
- Ecuador
- Prior art keywords
- compositions
- pharmaceutical composition
- aqueous
- selexipag
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se relaciona con composiciones farmacéuticas acuosas que comprenden el compuesto 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(metilsulfonil) acetamida; glicina; polisorbato 20; y un regulador de fosfato acuoso, en donde las cantidades relativas son como se describió en la descripción, en donde el pH de dicha composición farmacéutica está entre aproximadamente 7 y 8; con composiciones farmacéuticas liofilizadas preparadas a partir de dichas composiciones acuosas, y con composiciones acuosas reconstituidas de estas que son adecuadas para administración i.v. La invención se relaciona, además, con procesos para la preparación de dichas composiciones, y con su uso para el tratamiento de enfermedades y trastornos relacionados con el receptor IP.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055406 | 2017-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19072294A true ECSP19072294A (es) | 2019-11-30 |
Family
ID=61655736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201972294A ECSP19072294A (es) | 2017-03-08 | 2019-10-04 | Composición farmacéutica que comprende selexipag |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20200129506A1 (es) |
| EP (1) | EP3592391B1 (es) |
| JP (1) | JP6964679B2 (es) |
| KR (1) | KR102593075B1 (es) |
| CN (1) | CN110430900B (es) |
| AR (1) | AR111570A1 (es) |
| AU (1) | AU2018229750B2 (es) |
| BR (1) | BR112019018420A2 (es) |
| CA (1) | CA3055010A1 (es) |
| CL (1) | CL2019002511A1 (es) |
| CO (1) | CO2019009221A2 (es) |
| CR (1) | CR20190455A (es) |
| DO (1) | DOP2019000250A (es) |
| EA (1) | EA201992074A1 (es) |
| EC (1) | ECSP19072294A (es) |
| ES (1) | ES2880009T3 (es) |
| IL (1) | IL269061A (es) |
| JO (1) | JOP20190204A1 (es) |
| MA (1) | MA47816A (es) |
| MX (1) | MX2019010598A (es) |
| NI (1) | NI201900090A (es) |
| PE (1) | PE20191492A1 (es) |
| PH (1) | PH12019502033A1 (es) |
| PL (1) | PL3592391T3 (es) |
| SG (1) | SG11201907804QA (es) |
| TW (1) | TWI764996B (es) |
| WO (1) | WO2018162527A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3965767A1 (en) * | 2019-05-06 | 2022-03-16 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
| JP2022536623A (ja) * | 2019-06-11 | 2022-08-18 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療方法 |
| IL292354A (en) * | 2019-10-23 | 2022-06-01 | Actelion Pharmaceuticals Ltd | A pharmaceutical preparation containing Selexifag |
| JP2023512273A (ja) | 2020-01-31 | 2023-03-24 | アクテリオン ファーマシューティカルズ リミテッド | 制御放出セレキシパグ組成物 |
| TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
| WO2022215045A1 (en) * | 2021-04-08 | 2022-10-13 | Glenmark Pharmaceutical Limited | Lyophilized composition comprising selexipag |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| WO2023209731A1 (en) * | 2022-04-25 | 2023-11-02 | Msn Laboratories Private Limited, R&D Center | Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation |
| WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
| TW202404594A (zh) * | 2022-06-10 | 2024-02-01 | 日商日本新藥股份有限公司 | 醫藥組合物 |
| WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI316055B (es) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| DK1478339T3 (da) * | 2002-02-22 | 2008-08-25 | Schering Corp | Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf |
| CN104761509A (zh) | 2008-02-28 | 2015-07-08 | 日本新药株式会社 | 纤维化抑制剂 |
| WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | 勃起不全治療剤 |
| WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
| PT2292231E (pt) | 2008-06-23 | 2015-12-31 | Nippon Shinyaku Co Ltd | Agente terapêutico para a estenose do canal espinal |
| DK2289518T3 (en) | 2008-06-23 | 2017-01-16 | Nippon Shinyaku Co Ltd | Therapeutic agent for inflammatory bowel diseases |
| PT2447254T (pt) * | 2009-06-26 | 2018-01-04 | Nippon Shinyaku Co Ltd | Cristais |
| WO2011024874A1 (ja) | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| BR112013027009A2 (pt) * | 2011-04-19 | 2016-12-27 | Rigshospitalet | prostaciclina e análogos da mesa administrada durante cirurgia para prevenção e tratamento de derrame capilar |
| KR20140082649A (ko) | 2011-08-12 | 2014-07-02 | 아센디스 파마 에이에스 | 프로스타사이클린의 서방형 조성물 |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| EP3043774B1 (en) * | 2013-09-11 | 2020-11-04 | Eagle Biologics, Inc. | Liquid protein formulations containing ionic liquids |
| GB201400412D0 (en) * | 2014-01-10 | 2014-02-26 | Heart Biotech Ltd | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension |
| WO2017029594A1 (en) | 2015-08-17 | 2017-02-23 | Dr. Reddy's Laboratories Limited | Processes for preparation of selexipag and its amorphous form |
| EP3192502A1 (en) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
-
2017
- 2017-06-16 JO JOP/2019/0204A patent/JOP20190204A1/ar unknown
-
2018
- 2018-03-06 TW TW107107374A patent/TWI764996B/zh active
- 2018-03-07 JP JP2019548608A patent/JP6964679B2/ja active Active
- 2018-03-07 US US16/491,854 patent/US20200129506A1/en active Pending
- 2018-03-07 WO PCT/EP2018/055551 patent/WO2018162527A1/en unknown
- 2018-03-07 KR KR1020197029059A patent/KR102593075B1/ko active IP Right Grant
- 2018-03-07 CN CN201880016540.5A patent/CN110430900B/zh active Active
- 2018-03-07 AU AU2018229750A patent/AU2018229750B2/en not_active Expired - Fee Related
- 2018-03-07 MA MA047816A patent/MA47816A/fr unknown
- 2018-03-07 EA EA201992074A patent/EA201992074A1/ru unknown
- 2018-03-07 EP EP18711258.6A patent/EP3592391B1/en active Active
- 2018-03-07 PE PE2019001788A patent/PE20191492A1/es unknown
- 2018-03-07 BR BR112019018420A patent/BR112019018420A2/pt active Search and Examination
- 2018-03-07 SG SG11201907804QA patent/SG11201907804QA/en unknown
- 2018-03-07 ES ES18711258T patent/ES2880009T3/es active Active
- 2018-03-07 MX MX2019010598A patent/MX2019010598A/es unknown
- 2018-03-07 CR CR20190455A patent/CR20190455A/es unknown
- 2018-03-07 CA CA3055010A patent/CA3055010A1/en active Pending
- 2018-03-07 AR ARP180100522A patent/AR111570A1/es unknown
- 2018-03-07 PL PL18711258T patent/PL3592391T3/pl unknown
-
2019
- 2019-08-27 CO CONC2019/0009221A patent/CO2019009221A2/es unknown
- 2019-09-02 CL CL2019002511A patent/CL2019002511A1/es unknown
- 2019-09-02 IL IL26906119A patent/IL269061A/en unknown
- 2019-09-06 PH PH12019502033A patent/PH12019502033A1/en unknown
- 2019-09-06 NI NI201900090A patent/NI201900090A/es unknown
- 2019-10-02 DO DO2019000250A patent/DOP2019000250A/es unknown
- 2019-10-04 EC ECSENADI201972294A patent/ECSP19072294A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2880009T3 (es) | 2021-11-23 |
| IL269061A (en) | 2019-11-28 |
| BR112019018420A2 (pt) | 2020-04-14 |
| AU2018229750A1 (en) | 2019-09-12 |
| CR20190455A (es) | 2019-11-12 |
| JP2020509070A (ja) | 2020-03-26 |
| CO2019009221A2 (es) | 2019-08-30 |
| US20200129506A1 (en) | 2020-04-30 |
| NI201900090A (es) | 2020-03-11 |
| DOP2019000250A (es) | 2020-09-15 |
| MA47816A (fr) | 2020-01-15 |
| CL2019002511A1 (es) | 2020-01-17 |
| CN110430900A (zh) | 2019-11-08 |
| EP3592391A1 (en) | 2020-01-15 |
| SG11201907804QA (en) | 2019-09-27 |
| PE20191492A1 (es) | 2019-10-21 |
| AU2018229750B2 (en) | 2023-11-23 |
| WO2018162527A1 (en) | 2018-09-13 |
| JOP20190204A1 (ar) | 2019-09-05 |
| JP6964679B2 (ja) | 2021-11-10 |
| KR20190122803A (ko) | 2019-10-30 |
| MX2019010598A (es) | 2019-10-15 |
| EA201992074A1 (ru) | 2020-02-27 |
| EP3592391B1 (en) | 2021-04-21 |
| CN110430900B (zh) | 2023-09-19 |
| PH12019502033A1 (en) | 2020-06-15 |
| CA3055010A1 (en) | 2018-09-13 |
| TWI764996B (zh) | 2022-05-21 |
| PL3592391T3 (pl) | 2021-11-02 |
| TW201842910A (zh) | 2018-12-16 |
| AR111570A1 (es) | 2019-07-31 |
| KR102593075B1 (ko) | 2023-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19072294A (es) | Composición farmacéutica que comprende selexipag | |
| BR112022010349A2 (pt) | Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA202191559A1 (ru) | Модифицированные аминовые липиды | |
| EA202090890A1 (ru) | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| BR112018013979A2 (pt) | composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| EA201790950A1 (ru) | Способы и композиции, в частности, для лечения синдрома дефицита внимания | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| ECSP22040921A (es) | Composición farmacéutica que comprende selexipag | |
| BR112018009534A2 (pt) | composição farmacêutica contendo 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi }-n-(metilsulfonil)acetamida | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| BR112017019431A2 (pt) | material de implante de compósito | |
| EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
| CL2008002060A1 (es) | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |